Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB +2.25%71 Net Cash per Share is $1.09 as of Mar. 2026, which is 79% below its 10-year median of 5.11. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 303 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 74.92% on this metric.
The historical rank and industry rank for Cytek Biosciences's Net Cash per Share or its related term are showing as below:
CTKB'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.96 Med: 5.11 Max: 8.81
Current: 3.95
During the past 7 years, the highest Price-to-Net-Cash Ratio of Cytek Biosciences was 8.81. The lowest was 2.96. And the median was 5.11.
CTKB's Price-to-Net-Cash is ranked better than 74.92% of 303
companies
in the Medical Devices & Instruments industry
Industry Median: 8.04
vs CTKB: 3.95
Cytek Biosciences (NAS:CTKB) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Cytek Biosciences Net Cash per Share Related Terms
Cytek Biosciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, TCMD, CBLL: Net Cash per Share Comparison
For the Medical Devices subindustry, Cytek Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Cytek Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Net Cash per Share of $1.09 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Cytek Biosciences and its competitors. This is 79% below median its historical median of 5.11. Over the past decade, Cytek Biosciences' Net Cash per Share has ranged from 2.96 to 8.81. According to the industry distribution chart, Cytek Biosciences ranks #76 out of 303 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is Cytek Biosciences' Net Cash per Share too high?
Cytek Biosciences' current Net Cash per Share of $1.09 is 79% below median its 10-year median of 5.11. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 8.81. The Medical Devices & Instruments industry median Net Cash per Share is 8.04. Cytek Biosciences' value of $1.09 is 86.4% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #76 out of 303 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Net Cash per Share compare to CERS and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #76 out of 303 companies for Net Cash per Share. This puts Cytek Biosciences in the upper half of its industry. The industry median Net Cash per Share is 8.04. Cytek Biosciences' value of $1.09 is 86.4% below this benchmark. Historically, Cytek Biosciences' own Net Cash per Share has ranged from 2.96 to 8.81 over the past decade. While the company's 10-year median is 5.11 vs. the industry median of 8.04, Cytek Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 8.04, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Net Cash per Share of $1.09 is 86.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 8.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Net Cash per Share is $1.09, which is 79% below median its own 10-year median of 5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.31 — trading 26.1% below its estimated fair value. The current Net Cash per Share is $1.09, which is 79% below median its 10-year median of 5.11 and 86.4% below the Medical Devices & Instruments industry median of 8.04. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Net Cash per Share is $1.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.31 is trading 26.1% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Net Cash per Share: $1.09 (79% below median its 10-year median of 5.11)
GF Value™: $5.83 vs. price of $4.31 (26.1% below fair value)
Industry Position: 86.4% below the Medical Devices & Instruments median (#76 of 303)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
